ANXA10 has been recognized as a valuable diagnostic tool in differentiating liver PDAC metastases from cholangiocarcinoma [21] or other malignancies, with a sensitivity and specificity of 83% and 95%, respectively [22]. Here, ANXA10 is linked to cholangiocarcinoma.